Board of Directors
Robert Martell, M.D., Ph.D.*
Robert Martell has served on our board since September 2011. Since September 2015, Dr. Martell has served as Associate Chief for the Division of Hematology/Oncology and Attending Physician at Tufts Medical Center, and on faculty at Tufts University School of Medicine. During his time at Tufts, from September 2009 to September 2012, he was an Associate Professor at Tufts Medical Center and served as both the Director of the Neely Center for Clinical Cancer Research, and Leader of the Cancer Center's Program in Experimental Therapeutics. From 2012 to 2015, Dr. Martell served as Chief Medical Officer at TESARO (NASDAQ: TSRO), where he made key contributions to licensing and development of niraparib and the company’s immuno-oncology portfolio, as well as the NDA filing for Varubi. Prior to joining Tufts, he served as Vice President and Chief Medical Officer of MethylGene (TSE: MYG) (now Mirati Therapeutics), focused on the development of cancer therapeutics, including those targeting HDAC. Dr. Martell also served as Director of Oncology Global Clinical Research at Bristol-Myers Squibb Company, where he worked with molecular-targeted drugs in areas such as multi-target kinase inhibitors, including several of the pivotal studies for SPRYCEL, the panHER inhibitor program, CDK2 inhibitor and was involved in the Biologic Licensing Application (BLA) for Erbitux, an antibody that targets EGFR. He also worked at Bayer Pharmaceutical Division where he oversaw the Phase I and Phase II studies for Nexavar. He received his B.A. degree in chemistry from Kalamazoo College, his Ph.D. degree in pharmacology from the University of Michigan, and his M.D. degree from Wayne State University. He completed his internal medicine internship and residency and medical oncology fellowship at Duke University Medical Center where he was subsequently appointed Assistant Professor, Department of Medicine, Geriatrics and Medical Oncology.